ViiV Healthcare v. Hetero Labs: Dolutegravir ANDA Dispute Ends in Consent Judgment
ViiV Healthcare, Shionogi & Co., and ViiV Healthcare UK sued Hetero USA and Hetero Labs over US9242986 — the patent protecting dolutegravir, marketed as TIVICAY®. The parties settled within 222 days, with Hetero accepting a permanent injunction barring generic entry except as authorised under the settlement agreement.
A swift ANDA settlement locks Hetero out of the dolutegravir market
On 3 May 2024, ViiV Healthcare Company, Shionogi & Co., Ltd., and ViiV Healthcare UK (No. 3) Limited filed a Hatch-Waxman patent infringement action in the District of Delaware against Hetero USA, Inc. and multiple Hetero Labs Limited entities. The suit centred on US9242986 — a composition patent covering dolutegravir, the active ingredient in the blockbuster HIV integrase strand transfer inhibitor TIVICAY®. Hetero’s ANDA filing to market a generic version triggered the litigation.
The case resolved on 11 December 2024 via a consent judgment signed by Judge Mitchell S. Goldberg. Under the consent judgment, Hetero and its affiliates, successors, and assigns are permanently enjoined from infringing US9242986 by making, using, selling, offering to sell, importing, or distributing the ANDA product — except as specifically authorised under the separately negotiated settlement agreement. All claims, counterclaims, and affirmative defences were dismissed with prejudice, with no costs or attorneys’ fees awarded to either party.
At 222 days, the resolution is notably faster than typical contested Hatch-Waxman proceedings, suggesting the parties reached commercial accommodation relatively quickly — likely including a negotiated authorised-generic or market-entry date provision in the confidential settlement agreement, though the public record does not disclose those terms. The injunction’s carve-out language (‘except as specifically authorised pursuant to the Settlement Agreement’) is a standard indicator that Hetero may retain a future launch right; however, the precise trigger date and conditions remain undisclosed.
Filing to Consent Judgment in 222 days
222-day resolution — faster than the median Hatch-Waxman ANDA trial in Delaware
Consent judgment and injunction: what the resolution means for both parties
Consent judgment is a court order, not just a contract
A consent judgment carries the full force of a judicial order. Unlike a private settlement agreement, it is directly enforceable by the court — ViiV can return to Judge Goldberg to enforce Hetero’s injunction compliance without filing a new lawsuit. The District Court expressly retained jurisdiction for this purpose. All claims were dismissed with prejudice, meaning Hetero cannot reassert the same invalidity or non-infringement defences in a future action on this patent.
Dismissed with prejudiceViiV secures injunction and preserves dolutegravir exclusivity
The permanent injunction protects US9242986 against this specific Hetero ANDA product for the remainder of the patent term, except under settlement-authorised conditions. Critically, all of Hetero’s invalidity and non-infringement counterclaims were dismissed with prejudice — eliminating this challenge vector. ViiV retains the ability to enforce the injunction directly through the court, providing a low-friction enforcement mechanism against any breach.
Injunction securedHetero’s generic entry path now runs through settlement terms alone
Hetero accepted the injunction and dismissed all counterclaims with prejudice, foreclosing this litigation path for challenging US9242986’s validity. Any future market entry depends entirely on the confidential settlement agreement’s authorised-launch provisions. The ‘except as specifically authorised’ carve-out in the injunction suggests a negotiated entry date exists, but Hetero has no public fallback if that authorisation is conditioned on milestone events or a future licence fee.
Entry subject to licence termsTIVICAY® exclusivity reinforced; authorised generic timing is the key unknown
Dolutegravir remains one of the most commercially significant HIV antiretrovirals globally. This consent judgment — the seventh known ANDA settlement pattern for this compound — consistently signals that challengers find the composition patent difficult to invalidate at acceptable litigation cost. For other ANDA filers targeting dolutegravir generics, this outcome raises the effective barrier to contested litigation and may accelerate settlement discussions in parallel proceedings.
Patent barrier reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ViiV Healthcare, Co. | Company | Pharmaceutical IP holders — originator of dolutegravir HIV therapy, holders of US9242986Search in Eureka ↗ |
| Co-Plaintiff | Shionogi & Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Viiv Healthcare UK (No.3) Limited | Individual | Search in Eureka ↗ |
| Defendant | Hetero USA, Inc. | Company | Indian generic pharmaceutical manufacturer seeking US market entry via ANDA for dolutegravir tabletsSearch in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for ViiV Healthcare, Co.Search in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing ViiV Healthcare, Co.Search in Eureka ↗ |
| Defendant counsel | Cortlan S. Hitch | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Hetero USA, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Hetero USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Mitchell S. Goldberg | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s injunction language — ‘enjoined from infringing US9242986 … except as specifically authorised pursuant to the Settlement Agreement’ — operates as a permanent court order while simultaneously preserving a confidential commercial licence pathway. The with-prejudice dismissal of all counterclaims, including invalidity defences, has collateral estoppel implications: Hetero cannot relitigate the same defences in any future action concerning this patent and these products. The no-costs stipulation is consistent with negotiated parity settlements where neither party sought fee-shifting, suggesting a commercially balanced resolution rather than a one-sided capitulation.
US9242986 — Dolutegravir HIV integrase strand transfer inhibitor
US9242986 (application number US14/272823) is a composition patent covering dolutegravir — a second-generation HIV integrase strand transfer inhibitor (INSTI) that forms the backbone of numerous first-line antiretroviral regimens. The patent claims dolutegravir’s compound structure and pharmaceutical compositions, providing strong protection against generic substitution. Dolutegravir is marketed by ViiV Healthcare as TIVICAY® and is co-developed with Shionogi, which explains the joint plaintiff structure in this and related ANDA litigations.
Dolutegravir’s commercial profile is exceptional — it anchors several WHO-recommended first-line HIV regimens and generates multi-billion dollar annual revenues globally. US9242986 represents a critical exclusivity asset for ViiV and Shionogi. The consistent pattern of ANDA challengers resolving via consent judgment rather than contesting to trial strongly suggests the patent’s composition claims present a high invalidity hurdle. Any company developing HIV integrase inhibitor compounds, fixed-dose combinations containing dolutegravir, or dolutegravir-adjacent INSTI chemistry should treat this patent as a primary freedom-to-operate obstacle.
Should you run an FTO analysis against US9242986?
Any pharmaceutical company, contract manufacturer, or formulation developer working on HIV integrase inhibitor therapies — particularly those targeting dolutegravir, dolutegravir analogues, or INSTI fixed-dose combinations — should conduct a formal FTO analysis against US9242986 before committing to ANDA filing or clinical development. The consent judgment in this case does not resolve the patent’s validity publicly, meaning the patent remains fully enforceable against all other parties. The injunction here binds only Hetero’s specific ANDA product.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US9242986 against your compound structure or formulation, identify related ViiV and Shionogi portfolio patents that may present layered risk, and surface prior art that was not raised in this settled proceeding. Because all of Hetero’s invalidity counterclaims were dismissed with prejudice without a court merits ruling, the patent’s claim scope has not been judicially narrowed — making an independent claim-by-claim FTO analysis essential before any product development decision.
Run a freedom-to-operate analysis on US9242986B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving HIV antiviral patents in Delaware
Cases involving Hatch-Waxman ANDA challenges to HIV antiviral compound patents in Delaware District Court, including related dolutegravir and INSTI consent judgments.
What this case signals for the HIV antiviral IP landscape
A rapid consent judgment with permanent injunction reinforces ViiV’s dolutegravir fortress — but the authorised-generic carve-out is the commercial story.
Composition patents with Hatch-Waxman history rarely fall in early settlement
When an originator secures a consent judgment with full injunctive relief this quickly, it typically signals that the generic challenger’s ANDA paragraph IV certification faced strong composition patent claims. The with-prejudice dismissal of all counterclaims suggests Hetero’s invalidity arguments were not advanced past an early assessment stage.
The injunction carve-out is where the commercial deal lives
The phrase ‘except as specifically authorised pursuant to the Settlement Agreement’ is standard coded language for an agreed launch date. Competitors and payers tracking dolutegravir pricing should monitor the settlement agreement’s public disclosure obligations and any subsequent FDA tentative-approval notifications from Hetero as signals of the authorised entry window.
ViiV v Hetero — key questions answered
The case resolved on 11 December 2024 via a consent judgment entered by Judge Mitchell S. Goldberg in the District of Delaware. Hetero and its affiliates are permanently enjoined from infringing US9242986 except as authorised under a confidential settlement agreement. All claims and counterclaims were dismissed with prejudice, with no costs awarded to either party.
The case involves US9242986 (application US14/272823), a composition patent covering dolutegravir — the active ingredient in TIVICAY®, ViiV Healthcare’s second-generation HIV integrase strand transfer inhibitor. The patent is jointly held by ViiV Healthcare and Shionogi & Co., Ltd.
The injunction bars Hetero from infringing US9242986 through its ANDA product ‘except as specifically authorised pursuant to the Settlement Agreement.’ This carve-out language typically signals a negotiated authorised-launch date in the confidential agreement, meaning Hetero may retain a conditional future market-entry right. The precise terms are not publicly disclosed.
All of Hetero’s counterclaims — including any invalidity and non-infringement defences asserted against US9242986 — were dismissed with prejudice. This means Hetero is barred from relitigating those same defences in any future action involving this patent and the specific ANDA product. It does not affect other ANDA filers’ ability to assert invalidity independently.
Plaintiffs are ViiV Healthcare Company, Shionogi & Co., Ltd., and ViiV Healthcare UK (No. 3) Limited, represented by McCarter & English LLP. Defendants are Hetero USA, Inc., Hetero Labs Limited Unit-III, Hetero Labs Limited Unit-V, and Hetero Labs Limited, represented by Morris James LLP.
PatSnap Eureka searches patents and litigation data to answer instantly.